Related Experiment Video
Updated: Aug 2, 2026
12:02
Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 12, 2013
Developments in antiviral drug design, discovery and development in 2004
Nicholas A Meanwell1, Makonen Belema, David J Carini
1Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA. Nicholas.Meanwell@bms.com
Current Drug Targets. Infectious Disorders
|March 16, 2006
Summary
This review highlights 2004 advancements in antiviral drug discovery for clinical applications. Key progress was made in developing treatments for viruses including HIV, hepatitis, herpes, and respiratory infections.
Area of Science:
- Virology
- Medicinal Chemistry
- Clinical Pharmacology
Background:
- Antiviral agents are crucial for managing viral infections.
- The year 2004 saw significant research efforts in antiviral drug development.
- Numerous viral pathogens pose global health challenges.
Purpose of the Study:
- To summarize progress in antiviral agent design, discovery, and development in 2004.
- To review the clinical utility of emerging antiviral therapies.
- To provide an overview of advancements against a wide range of viruses.
Main Methods:
- Literature review of research published in 2004.
- Identification and characterization of novel antiviral compounds.
- Assessment of clinical trial data for antiviral agents.
Main Results:
- Progress in developing inhibitors for Human Immunodeficiency Virus (HIV).
- Advancements in therapies for Hepatitis B (HBV) and Hepatitis C (HCV).
- Developments in treating herpesviruses (HSV-1, HSV-2, VZV, EBV, CMV), respiratory viruses (Influenza, RSV, hMPV, picornaviruses, measles, SARS-CoV), HPV, rotavirus, Ebola, and West Nile virus.
Conclusions:
- The year 2004 demonstrated substantial progress in the pipeline for antiviral drugs.
- Continued research is essential for addressing unmet needs in viral disease treatment.
- The reviewed developments indicate a promising future for clinical antiviral therapies.
Related Concept Videos
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...